COMMUNIQUÉS West-GlobeNewswire

Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer
05/03/2026
CELEBRATION, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference
05/03/2026
MELBOURNE, Australia, March 05, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, [...]
Collegium to Present New Real-World Data at PainConnect 2026
05/03/2026
STOUGHTON, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present two posters featuring real-world data from its portfolio of differentiated pain [...]
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
05/03/2026
Initiation of Phase 3 MASH trial planned for 2026 Pemvidutide granted FDA Breakthrough Therapy Designation in MASH Topline data from RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder (AUD) expected in third [...]
XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders
05/03/2026
CALGARY, Alberta, March 05, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on [...]
MediWound Reports Fourth Quarter and Full Year 2025 Financial Results
05/03/2026
EscharEx ® Phase III VALUE trial advancing as planned Expanded NexoBrid ® manufacturing facility operational ; regulatory approvals expected in 2026 $17 million revenue in 2025 ; $54 million in cash at year-end; 2026– [...]
Avalyn Appoints Biopharmaceutical Industry Leader Kate Haviland to Board of Directors
05/03/2026
Appointment adds extensive commercial, operational, and strategic leadership experience as Avalyn advances its pipeline of inhaled therapies for pulmonary fibrosis BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- Avalyn [...]
Herantis Pharma releases 2H and FY 2025 report today
05/03/2026
Herantis Pharma Plc | Company Release | March 5, 2026 at 08:00:00 EET Espoo, Finland, March 5, 2026: Herantis Pharma Plc ("Herantis") a clinical-stage company developing disease-modifying therapies to stop the [...]
Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort
05/03/2026
The Company is expected to finalize the Clinical Study Report (CSR) in Q2 2026 to support planned end of Phase 2 (EOP2) meeting with the FDA PHILADELPHIA, March 05, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: [...]
Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights
05/03/2026
Phase 1 clinical trial of SL-325 ongoing, with data expected in the second quarter of 2026 – Phase 2 clinical trial of SL-325 in patients with Crohn’s disease expected to initiate in the third quarter of 2026 – AUSTIN, [...]
Immatics Announces Full Year 2025 Financial Results and Business Update
05/03/2026
Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; anzu-cel received Orphan Drug Designation from the [...]
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat
05/03/2026
ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO, March 05, 2026 (GLOBE [...]
GH Research Reports Full Year 2025 Financial Results and Provides Business Update
05/03/2026
Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP congresses GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment Cash, cash equivalents [...]
Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals
05/03/2026
Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development milestone associated [...]
Oculis Publishes 2025 Consolidated Financial Statements
05/03/2026
ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Following the Company‘s press release published on March 3, the audited consolidated financial statements for the financial year 2025 and the MD&A, which have now [...]
Oculis to Participate in Upcoming Investor Conferences
05/03/2026
ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro- [...]
Oculis to Participate in Upcoming Investor Conferences
05/03/2026
ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro- [...]
Communiqué de presse : Le Conseil d’administration de Sanofi propose la nomination de Christel Heydemann en qualité d’administratrice indépendante
05/03/2026
Le Conseil d’administration de Sanofi propose la nomination de C hristel Heydemann en qualité d’administrat rice indépendant e Paris , le 5 mars 202 6 . Le Conseil d’administration de Sanofi a décidé de proposer, dans [...]
Swarm Oncology appoints Bernhard Ehmer as Chairman
05/03/2026
Company announces manufacturing readiness and financing extension ahead of first-in-human clinical study London, United Kingdom, March 5, 2026, Swarm Oncology Ltd. (“Swarm Oncology” or “Swarm” or “the Company”), a [...]

Pages